A. Pegu

HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV vectored immunotherapy in humanized mice

This paper uses humanized mice to study how HIV resistance to broadly neutralizing antibodies (bNAbs) affects the efficacy of AAV-delivered immunotherapy, finding that escape mutation fitness costs and resistance benefits determine therapeutic success.

A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization

This paper develops multispecific antibodies that neutralize all SARS-CoV-2 variants, including Omicron, by targeting multiple epitopes on the spike protein.

Broadly neutralizing antibodies target the coronavirus fusion peptide

The paper identifies six monoclonal antibodies that broadly neutralize coronaviruses by targeting the conserved fusion peptide.

Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones

The paper examines antibody responses to SARS-CoV-2 variants, finding convergent epitope specificities, V gene usage, and public B cell clones across different variants.

Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability

This paper identifies an antibody, WS6, from a mouse immunized with SARS-CoV-2 spike mRNA, which neutralizes diverse beta-coronaviruses by targeting a conserved helical epitope on the S2 subunit.

Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529

The paper identifies potent monoclonal antibodies that neutralize the B.1.1.529 SARS-CoV-2 variant and reveals structural mechanisms enabling their effectiveness.

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants

This study assesses the durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants over seven months, finding persistent but reduced binding and functional responses.

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant

This study assesses neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant in convalescent and vaccinated individuals, finding it is 6.8-fold more resistant but still neutralizable.

CCR2-dependent monocyte-derived cells restrict SARS-CoV-2 infection

This study identifies a CCR2-dependent monocyte-derived cell mechanism that restricts SARS-CoV-2 infection and inflammation in the lungs of mice.

A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope

The paper identifies an antibody that neutralizes all SARS-CoV-2 variants by targeting a conserved epitope on the spike protein.

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants

This study identifies ultrapotent bispecific antibodies that neutralize emerging SARS-CoV-2 variants by targeting multiple spike protein regions, showing efficacy in vitro and in a hamster model.

Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants

The paper identifies ultrapotent antibodies from convalescent donors that neutralize SARS-CoV-2 variants and reduce escape mutant generation.

A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone

This paper develops a nanoparticle platform for displaying trimeric antigens, showing that SARS-CoV-2 spike-LuS nanoparticles induce 25-fold higher neutralizing responses than spike alone.

Protection of rhesus macaques against vaginal SHIV challenges by VRC01 and an anti-α4β7 antibody

This study shows that combining VRC01 and Rh-4β7 antibodies delays SHIV infection, preserves CD4+ T cells, and alters immune responses in macaques.